Publications by authors named "A Boutis"
Incidence, characteristics and outcome of therapy-related myeloid neoplasms in women with epithelial ovarian cancer after exposure to poly-ADPribose polymerase inhibitors: A cancer center experience.
Int J Cancer
December 2024
Poly(ADP-ribose) polymerase inhibitors (PARPi) target the DNA repair pathways and have been established in epithelial ovarian cancer (EOC) as maintenance therapy inducing prolonged survival. However, recently published data showed that PARPi may increase the risk of therapy-related myeloid neoplasms (t-MN) including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Herein, we investigated the incidence, characteristics, and management of t-MN among EOC patients after exposure to PARPi in a Greek Cancer Center.
View Article and Find Full Text PDFPurpose: The pan-cancer presence of microsatellite instability (MSI)-positive tumors demonstrates its clinical utility as an agnostic biomarker for identifying immunotherapy-eligible patients. Additionally, MSI is a hallmark of Lynch syndrome (LS), the most prevalent cancer susceptibility syndrome among patients with colorectal and endometrial cancer. Therefore, MSI-high results should inform germline genetic testing for cancer-predisposing genes.
View Article and Find Full Text PDFArticle Synopsis
- The study explores the effectiveness of PARP inhibitors in treating various cancers, focusing on the relationship between genomic loss of heterozygosity (gLOH) and gene alterations in patients.
- It analyzes 406 tumor samples using next-generation sequencing (NGS), highlighting that nearly 21% of tumors displayed homologous recombination (HR) variations, while about 5% had gene alterations.
- The findings suggest a strong correlation between high gLOH percentages and positive gene alterations, indicating that assessing gLOH could help identify more patients who may benefit from PARP inhibitors.
Background/aim: Nivolumab is an FDA-approved immune checkpoint inhibitor (ICI) for patients with advanced, pre-treated non-small cell lung cancer (NSCLC). However, treatment profiles and patient outcomes often differ in routine clinical practice while the financial impact of approved therapies is largely unknown. In this study, we investigated the efficacy, tolerability, and economic impact of nivolumab in real-world settings (RWS) in Greece.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to gather real-world data on the EGFR mutational profile and treatment strategies for advanced non-small-cell lung cancer (NSCLC) patients after first/second-generation EGFR-TKI treatment.
- Ninety-six patients were enrolled in Greece, with re-biopsies conducted for some who were negative for the T790M mutation.
- Results showed that 21.9% of patients were T790M-positive, and those receiving third-generation EGFR-TKIs had better outcomes, highlighting the importance of mutational status and treatment choices in improving response rates and progression-free survival.